Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)? [Yahoo! Finance]
Rallybio Corporation (RLYB)
Company Research
Source: Yahoo! Finance
short interest, alongside the announcement of a $12.5 million milestone payment from Rallybio related to the advancement of REV102 for hypophosphatasia. An intriguing detail is that Recursion's AI capabilities have expanded through the co-development of Boltz-2 with MIT, highlighting the company's ongoing investment in cutting-edge drug discovery technology. We'll explore how increased focus on the possibility of a short squeeze could influence Recursion Pharmaceuticals' investment narrative going forward. These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. Recursion Pharmaceuticals Investment Narrative Recap To be a shareholder in Recursion Pharmaceuticals, investors typically need to believe that AI-driven drug discovery will translate into successful clinical development and eventual commercialization. The recent milestone payment from Rallybio and exp
Show less
Read more
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rallybio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire
- Rallybio (NASDAQ:RLYB) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RLYB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- Rallybio (NASDAQ:RLYB) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RLYB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
RLYB
Earnings
- 5/8/25 - In-Line
RLYB
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- RLYB's page on the SEC website